|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
La Merie Publishing, May 2012, Pages: 46
The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, RNA- and microorganism-based therapies against infection with Pseudomonas aeruginosa as of May 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Pseudomonas aeruginosa is an opportunistic gram-negative bacteria that lives in soil, water, and even in environments like hot tubs. For most healthy people, this bacteria seldom poses a problem. Pseudomonas aeruginosa is much more dangerous to populations who have weak immune systems, the elderly, and those who have been hospitalized for long periods of time. People with cystic fibrosis and with full-blown AIDS frequently die from infections created by the bacteria. Hospital-acquired pneumonia, particularly ventilator-associated pneumonia , causes considerable morbidity and mortality despite antimicrobial therapy and advances in supportive care. It is the second most frequent nosocomial infection and is the major cause of death among hospital-acquired infections.
The report includes a compilation of currently active projects in development of vaccines, antibodies, peptides and small molecules as well as of DNA-, RNA- and microorganism-based therapies targeting Pseudomonas aeruginosa for prophylaxis and treatment of P. aeruginosa infection. In addition, the report lists company-specific R&D pipelines of P. aeruginosa Vaccines & Therapeutics.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance
Competitor Analysis: Biologic and Immune Therapy of Staphylococcus Aureus Infections
Drug Delivery in Cancer - Technologies, Markets and Companies
Competitor Analysis: RSV Vaccines and Therapeutics
Innovations in Combating Infectious Diseases: Opportunities in Therapeutics and Diagnostics through Application of Proteomics, Genomics, Nanotechnology, and Novel Sources of Lead Generation
Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
Antibiotics and Drug Resistance 2008
Competitor Analysis: Cancer Vaccines
Future Infectious Disease Testing Market: Growth Opportunities and Business Expansion Strategies
|
|
|
|
